The effect of n-3 polyunsaturated fatty acids on leukotriene B4 and leukotriene B5 production from stimulated neutrophil granulocytes in patients with chronic kidney disease

Ayodele, 2010, Burden of chronic kidney disease: an international perspective, Adv. Chronic Kidney Dis., 17, 215, 10.1053/j.ackd.2010.02.001 Lysaght, 2002, Maintenance dialysis population dynamics: current trends and long-term implications, J. Am. Soc. Nephrol., 13, S37, 10.1681/ASN.V13suppl_1s37 Fassett, 2010, Omega-3 polyunsaturated fatty acids in the treatment of kidney disease, Am. J. Kidney Dis., 56, 728, 10.1053/j.ajkd.2010.03.009 Pestka, 2010, n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis, Prostaglandins Leukot. Essent. Fatty Acids, 82, 251, 10.1016/j.plefa.2010.02.013 Tonelli, 2005, Biomarkers of inflammation and progression of chronic kidney disease, Kidney Int., 68, 237, 10.1111/j.1523-1755.2005.00398.x Rodriguez-Iturbe, 2010, The role of tubulointerstitial inflammation in the progression of chronic renal failure, Nephron Clin. Pract., 116, c81, 10.1159/000314656 Donadio, 2001, n-3 Fatty acids and their role in nephrologic practice, Curr. Opin. Nephrol. Hypertens., 10, 639, 10.1097/00041552-200109000-00014 Lauretani, 2009, Omega-3 and renal function in older adults, Curr. Pharm. Des., 15, 4149, 10.2174/138161209789909719 Calder, 2006, n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases, Am. J. Clin. Nutr., 83, 1505S, 10.1093/ajcn/83.6.1505S Goodnow, 2010, Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1, J. Med. Chem., 53, 3502, 10.1021/jm1001919 Badr, 1992, Five-lipoxygenase products in glomerular immune injury, J. Am. Soc. Nephrol., 3, 907, 10.1681/ASN.V34907 Robinson, 2006, Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids, Am. J. Cardiol., 98, 39i, 10.1016/j.amjcard.2005.12.026 Lee, 1984, Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product, J. Biol. Chem., 259, 2383, 10.1016/S0021-9258(17)43363-1 Goldman, 1983, Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid, Biochem. Biophys. Res. Commun., 117, 282, 10.1016/0006-291X(83)91572-3 Noiri, 2000, An in vivo approach showing the chemotactic activity of leukotriene B(4) in acute renal ischemic-reperfusion injury, Proc. Natl. Acad. Sci. USA, 97, 823, 10.1073/pnas.97.2.823 Spurney, 1994, Fish oil feeding modulates leukotriene production in murine lupus nephritis, Prostaglandins, 48, 331, 10.1016/0090-6980(94)90032-9 Yared, 1991, Functional significance of leukotriene B4 in normal and glomerulonephritic kidneys, J. Am. Soc. Nephrol., 2, 45, 10.1681/ASN.V2145 Nakao, 1997, Long-term effects of LTB4 antagonist on lipid induced renal injury, Kidney Int. Suppl., 63, S236 Suzuki, 1999, The leukotriene B4 receptor antagonist ONO-4057 inhibits nephrotoxic serum nephritis in WKY rats, J. Am. Soc. Nephrol., 10, 264, 10.1681/ASN.V102264 Taccone-Gallucci, 2006, N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity, Kidney Int., 69, 1450, 10.1038/sj.ki.5000291 Wu, 2009, Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis, Am. J. Pathol., 174, 115, 10.2353/ajpath.2009.080671 Wall, 2010, Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids, Nutr. Rev., 68, 280, 10.1111/j.1753-4887.2010.00287.x Clark, 1989, Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus, Kidney Int., 36, 653, 10.1038/ki.1989.242 Mickleborough, 2006, Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma, Chest, 129, 39, 10.1378/chest.129.1.39 Lossl, 1999, The effect of n-3 fatty acids on leukotriene formation from neutrophils in patients on hemodialysis, Lipids, 34 Panchaud, 2006, Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial, Clin. Nutr., 25, 418, 10.1016/j.clnu.2005.10.011 Svensson, 2004, The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF, Am. J. Kidney Dis., 44, 77, 10.1053/j.ajkd.2004.03.024 Varming, 1995, The effect of n-3 fatty acids on neutrophil chemiluminescence, Scand. J. Clin. Lab. Invest., 55, 47, 10.3109/00365519509075377 Ferrante, 1978, A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique, J. Immunol. Methods, 24, 389, 10.1016/0022-1759(78)90143-6 Vogt, 2010, Serum concentrations of matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1 and alpha2-macroglobulin in healthy subjects after supplementation with different doses of marine n-3 fatty acids, Cell. Mol. Biol. (Noisy-le-grand), 56, 102 Hwang, 1988, Dietary linolenic acid and longer-chain n-3 fatty acids: comparison of effects on arachidonic acid metabolism in rats, J. Nutr., 118, 427, 10.1093/jn/118.4.427 Grimminger, 1992, Ligand-operated synthesis of 4-series and 5-series leukotrienes in human neutrophils: critical dependence on exogenous free fatty acid supply, Mol. Pharmacol., 41, 757 Powell, 1995, Formation of a 5-oxo metabolite of 5,8,11,14,17-eicosapentaenoic acid and its effects on human neutrophils and eosinophils, J. Lipid Res., 36, 2590, 10.1016/S0022-2275(20)41095-8 Friedman, 2010, Omega-3 fatty acid supplementation in advanced kidney disease, Semin. Dial., 23, 396, 10.1111/j.1525-139X.2010.00748.x Vanholder, 2005, Chronic kidney disease as cause of cardiovascular morbidity and mortality, Nephrol. Dial. Transplant., 20, 1048, 10.1093/ndt/gfh813 Svensson, 2006, N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial, Clin. J. Am. Soc. Nephrol., 1, 780, 10.2215/CJN.00630206